The ELF Test stands for Enhanced Liver Fibrosis. This test was approved by the FDA in 2021 as a prognostic test for patients with a progressive form of fatty liver disease known as NASH with advanced fibrosis. At Atlanta Endocrine Associates, Dr. Scott Isaacs is a fatty liver expert and offers accurate diagnosis and state-of-the-art treatment of fatty liver disease and hepatic hypothyroidism. To learn more, contact the office in Atlanta, Georgia or request an appointment online.
ELF measures 3 markers of liver fibrosis:
The ELF test allows doctors to assess the risk of disease progression in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) with a simple blood test instead of a more invasive liver biopsy. The ELF Test has been extensively studied and validated. The test assesses active fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a marker for prognosis. The ELF test has been a game-changer for my approach to patients with NAFLD because it is a simple test that I can order from Quest or LabCorp. Although the test is FDA approved as a prognostic test for patients with NASH and advanced fibrosis, I also use test as a diagnostic test to identify high-risk patients who have indeterminate FIB-4 scores. This technique for risk assessment has been recommended in the recent AACE NAFLD Guidelines.
Dr. Isaacs discusses the endocrinologist perspective of the ELF Test for Siemens Healthineers.
If you’d like to learn more about cardiometabolic disease, diabetes, fatty liver disease, or permanent weight loss, please feel free to call us or schedule an appointment with Dr. Isaacs in Atlanta, GA using the online booking tool on this website.